The current place of probiotics in the treatment of pouchitis

doi:10.3877/cma.j.issn.2095-3224.2017.01.013

Abstract

Abstract:

Pouchitis is the common complication of modest to severe ulcerative colitis patients after ileal pouch-anal anastomosis and mainfest itself with increased stool frequency, rectal bleeding, abdominal cramping and fever. The pathogenesis of pouchitis remains incompletely elucidate, however, most researchers believe that the change of the pouch flora (disorder) would lead to the immune activation and inflammation. Therefore probiotics treatment in pouchitis against in the flora disorder is concerned by many researchers both at home and board. The pathogenesis of pouchitis and probiotics treatment was as follows.

Key words: Digestive system, Therapy, Pouchitis, Ileal pouch-anal anastomosis, Probiotics

Senyang Gao, Gang Liu. The current place of probiotics in the treatment of pouchitis[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(01): 60-63.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.01.013

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I01/60

References 42

[1]	Gionchetti P, Calafiore A, Riso D, et al. The role of antibiotics and probiotics in pouchitis [J]. Ann Gastroenterol, 2012, 25(2): 100-105.
[2]	Madden MV, Farthing MJ, Nicholls RJ. Inflammation in ileal reservoirs: ′Pouchitis′ [J]. GUT, 1990, 31(3): 247-249.
[3]	Nicholls RJ, Belliveau P, Neill M, et al. Restorative proctocolectomy with ileal reservoir: A pathophysiological assessment [J]. GUT, 1981, 22(6): 462-468.
[4]	Ruseler-van EJ, Schouten WR, van Lieshout LM. Pouchitis: Result of microbial imbalance? [J]. GUT, 1994, 35(5): 658-664.
[5]	Iwaya A, Iiai T, Okamoto H, et al. Change in the bacterial flora of pouchitis [J]. Hepatogastroenterology, 2006, 53(67): 55-59.
[6]	Falk A, Olsson C, Ahrne S, et al. Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens [J]. Scand J Gastroenterol, 2007, 42(8): 973-985.
[7]	Zella GC, Hait EJ, Glavan T, et al. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis [J]. INFLAMM BOWEL DIS, 2011, 17(5): 1092-1100.
[8]	McLaughlin SD, Walker AW, Churcher C, et al. The bacteriology of pouchitis: A molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing [J]. ANN SURG, 2010, 252(1): 90-98.
[9]	Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults [J]. GUT, 2011, 60(5): 571-607.
[10]	Gionchetti P, Rizzello F, Venturi A, et al.Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial [J]. GASTROENTEROLOGY, 2000, 119(2): 305-309.
[11]	Islam SU. Clinical uses of probiotics [J]. Medicine(Baltimore), 2016, 95(5): e2658.
[12]	Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [J]. GASTROENTEROLOGY, 2003, 124(5): 1202-1209.
[13]	Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells [J]. INFLAMM BOWEL DIS, 2008, 14(5): 662-668.
[14]	Gosselink MP, Schouten WR, van Lieshout LM, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG [J]. DIS COLON RECTUM, 2004, 47(6): 876-884.
[15]	Yasueda A, Mizushima T, Nezu R, et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis [J]. SURG TODAY, 2016, 46(8): 939-949.
[16]	Elahi B, Nikfar S, Derakhshani S, et al. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials [J]. Dig Dis Sci, 2008, 53(5): 1278-1284.
[17]	Singh S, Stroud AM, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis [J]. Cochrane Database Syst Rev, 2015, 23(11): D1176.
[18]	Bengtsson J, Adlerberth I, Ostblom A, et al.Effect of probiotics(Lactobacillus plantarum 299 plus Bifidobacterium Cure21)in patients with poor ileal pouch function: A randomised controlled trial [J]. Scand J Gastroenterol, 2016, 51(9): 1087-1092.
[19]	Gionchetti P, Rizzello F, Morselli C, et al.High-dose probiotics for the treatment of active pouchitis [J]. DIS COLON RECTUM, 2007, 50(12): 2075-2082, 2082-2084.
[20]	Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis [J]. Scand J Gastroenterol, 2005, 40(1): 43-51.
[21]	Tomasz B, Zoran S, Jaroslaw W, et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: A randomized prospective study [J]. BIOMED RES INT, 2014, 2014: 208064.
[22]	Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora [J]. Aliment Pharmacol Ther, 2003, 17(4): 509-515.
[23]	Uchino M, Ikeuchi H, Matsuoka H, et al. Topical tacrolimus therapy for antibiotic-refractory pouchitis [J]. DIS COLON RECTUM, 2013, 56(10): 1166-1173.
[24]	Wall GC, Schirmer LL, Anliker LE, et al. Pharmacotherapy for acute pouchitis [J]. ANN PHARMACOTHER, 2011, 45(9): 1127-1137.
[25]	Mimura T, Rizzello F, Helwig U, et al.Once daily high dose probiotic therapy(VSL#3)for maintaining remission in recurrent or refractory pouchitis [J]. GUT, 2004, 53(1): 108-114.
[26]	Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis [J]. Cochrane Database Syst Rev, 2010, 16(6): D1176.
[27]	Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in clinical practice [J]. Aliment Pharmacol Ther, 2005, 22(8): 721-728.
[28]	Kanauchi O, Matsumoto Y, Matsumura M, et al. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease [J]. Curr Pharm Des, 2005, 11(8): 1047-1053.
[29]	Stephani J, Radulovic K, Niess JH. Gut microbiota, probiotics and inflammatory bowel disease [J]. Arch Immunol Ther Exp(Warsz), 2011, 59(3): 161-177.
[30]	Mack DR, Ahrne S, Hyde L, et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro [J]. GUT, 2003, 52(6): 827-833.
[31]	Caballero-Franco C, Keller K, De Simone C, et al. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells [J]. Am J Physiol Gastrointest Liver Physiol, 2007, 292(1): G315-G322.
[32]	Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease [J]. Curr Gastroenterol Rep, 2012, 14(4): 324-333.
[33]	Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity [J]. PLOS ONE, 2007, 2(12): e1308.
[34]	Karczewski J, Troost FJ, Konings I, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier [J]. Am J Physiol Gastrointest Liver Physiol, 2010, 298(6): G851-G859.
[35]	Kotzampassi K, Giamarellos-Bourboulis EJ. Probiotics for infectious diseases: More drugs, less dietary supplementation [J]. Int J Antimicrob Agents, 2012, 40(4): 288-296.
[36]	Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus [J]. LETT APPL MICROBIOL, 2007, 45(4): 454-460.
[37]	Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease [J]. Curr Gastroenterol Rep, 2012, 14(4): 324-333.
[38]	Mack DR. Probiotics in inflammatory bowel diseases and associated conditions [J]. NUTRIENTS, 2011, 3(2): 245-264.
[39]	Macho FE, Pot B, Grangette C. Beneficial effect of probiotics in IBD: Are peptidogycan and NOD2 the molecular key effectors? [J]. Gut Microbes, 2011, 2(5): 280-286.
[40]	Prisciandaro L, Geier M, Butler R, et al. Probiotics and their derivatives as treatments for inflammatory bowel disease [J]. INFLAMM BOWEL DIS, 2009, 15(12): 1906-1914.
[41]	Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus [J]. LETT APPL MICROBIOL, 2007, 45(4): 454-460.
[42]	Stephani J, Radulovic K, Niess JH. Gut microbiota, probiotics and inflammatory bowel disease [J]. Arch Immunol Ther Exp(Warsz), 2011, 59(3): 161-177.

Please choose a citation manager

Content to export